 | |
| Clinical data | |
|---|---|
| Trade names | Priftin |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a616011 |
| License data |
|
|
Routes of administration | By mouth |
| Drug class | Macrolactam |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | increases when administered with food |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C47H64N4O12 |
| Molar mass | 877.031 g·mol−1 |
| 3D model ( JSmol) | |
| Melting point | 179 to 180 °C (354 to 356 °F) |
| |
| |
| (verify) | |
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. [3] In active tuberculosis it is used together with other antituberculosis medications. [3] In latent tuberculosis it is typically used with isoniazid. [4] It is taken by mouth. [3]
Common side effects include low neutrophil counts in the blood, elevated liver enzymes, and white blood cells in the urine. [3] Serious side effects may include liver problems or Clostridium difficile associated diarrhea. [3] It is unclear if use during pregnancy is safe. [3] Rifapentine is in the rifamycin family of medication and works by blocking DNA-dependent RNA polymerase. [3]
Rifapentine was approved for medical use in the United States in 1998. [3] It is on the World Health Organization's List of Essential Medicines. [5] In the United States it costs $100–200 per month. [6] In many areas of the world it is not easy to get as of 2015. [7]
- ^ "Rifapentine (Priftin) Use During Pregnancy". Drugs.com. 2 December 2019. Archived from the original on 26 November 2020. Retrieved 16 March 2020.
-
^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ a b c d e f g h "Rifapentine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ^ World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 35–8. hdl: 10665/189763. ISBN 9789241209946. ISSN 0512-3054. WHO technical report series;994.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 53. ISBN 9781284057560.
- ^ Nieburg, Phillip; Dubovi, Talia; Angelo, Sahil (2015). Tuberculosis—A Complex Health Threat: A Policy Primer of Global TB Challenges. Rowman & Littlefield. p. 15. ISBN 9781442240957. Archived from the original on 2016-12-20.
|
| |
| Clinical data | |
|---|---|
| Trade names | Priftin |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a616011 |
| License data |
|
|
Routes of administration | By mouth |
| Drug class | Macrolactam |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | increases when administered with food |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C47H64N4O12 |
| Molar mass | 877.031 g·mol−1 |
| 3D model ( JSmol) | |
| Melting point | 179 to 180 °C (354 to 356 °F) |
| |
| |
| (verify) | |
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. [3] In active tuberculosis it is used together with other antituberculosis medications. [3] In latent tuberculosis it is typically used with isoniazid. [4] It is taken by mouth. [3]
Common side effects include low neutrophil counts in the blood, elevated liver enzymes, and white blood cells in the urine. [3] Serious side effects may include liver problems or Clostridium difficile associated diarrhea. [3] It is unclear if use during pregnancy is safe. [3] Rifapentine is in the rifamycin family of medication and works by blocking DNA-dependent RNA polymerase. [3]
Rifapentine was approved for medical use in the United States in 1998. [3] It is on the World Health Organization's List of Essential Medicines. [5] In the United States it costs $100–200 per month. [6] In many areas of the world it is not easy to get as of 2015. [7]
- ^ "Rifapentine (Priftin) Use During Pregnancy". Drugs.com. 2 December 2019. Archived from the original on 26 November 2020. Retrieved 16 March 2020.
-
^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ a b c d e f g h "Rifapentine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ^ World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 35–8. hdl: 10665/189763. ISBN 9789241209946. ISSN 0512-3054. WHO technical report series;994.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 53. ISBN 9781284057560.
- ^ Nieburg, Phillip; Dubovi, Talia; Angelo, Sahil (2015). Tuberculosis—A Complex Health Threat: A Policy Primer of Global TB Challenges. Rowman & Littlefield. p. 15. ISBN 9781442240957. Archived from the original on 2016-12-20.